GS
REGN icon

GTS Securities’s Regeneron Pharmaceuticals REGN Stock Holding History

GTS Securities’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$593K Sell
767
-349
-31% -$267K 0.02% 650
2025
Q4 		$861K Sell
1,116
-1,387
-55% -$942K 0.03% 505
2025
Q3 		$1.41M Buy
2,503
+1,697
+211% +$960K 0.05% 301
2025
Q2 		$423K Buy
806
+87
+12% +$48.6K 0.02% 731
2025
Q1 		$456K Sell
719
-628
-47% -$432K 0.02% 734
2024
Q4 		$960K Sell
1,347
-3,047
-69% -$2.56M 0.05% 343
2024
Q3 		$4.62M Sell
4,394
-3,345
-43% -$3.72M 0.01% 943
2024
Q2 		$8.13M Buy
7,739
+4,184
+118% +$4.06M 0.02% 586
2024
Q1 		$3.42M Sell
3,555
-183
-5% -$174K 0.01% 1108
2023
Q4 		$3.28M Buy
3,738
+3,143
+528% +$2.59M 0.01% 1293
2023
Q3 		$490K Buy
+595
New +$468K ﹤0.01% 2652

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

GTS Securities's REGN Position: Q1 2026 in Review

GTS Securities reduced its Regeneron Pharmaceuticals (REGN) stake by 31% in Q1 2026, selling an estimated $267K and leaving 767 shares worth $593K. The position accounts for 0.02% of the portfolio, ranked #650.

GTS Securities first reported a position in REGN in Q3 2023 and has held it in 11 quarters since. The position peaked at $8.13M in Q2 2024. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • GTS Securities held 767 shares of Regeneron Pharmaceuticals worth $593K as of Q1 2026.
  • GTS Securities sold 349 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $267K.
  • Regeneron Pharmaceuticals made up 0.02% of GTS Securities's portfolio in Q1 2026, its #650 holding.
  • GTS Securities first reported a position in Regeneron Pharmaceuticals in Q3 2023 and has held it in 11 quarters since.
  • GTS Securities's Regeneron Pharmaceuticals position peaked at $8.13M in Q2 2024.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on GTS Securities's 13F filing for Q1 2026, filed 15 May 2026.